Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Amgen : Today's Research Report Coverage on Biotech Stocks -- Marinus Pharma, NewLink Genetics, Akcea Therapeutics, and Amgen

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 12:31pm CET

NEW YORK, October 2, 2017 /PRNewswire/ --

If you want a Stock Review on MRNS, NLNK, AKCA, or AMGN then come over to http://dailystocktracker.com/register and sign up for your free customized report. On Friday, September 29, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, DailyStockTracker.com assessed the following Biotechnology equities this morning: Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), NewLink Genetics Corp. (NASDAQ: NLNK) , Akcea Therapeutics Inc. (NASDAQ: AKCA), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at:

http://dailystocktracker.com/register Marinus Pharmaceuticals 

On Friday, shares in Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc. recorded a trading volume of 1.58 million shares. The stock ended at $5.87, rising 5.01% from the last trading session. The Company's shares have gained 101.72% in the last month, 328.47% over the previous three months, 193.50% in the last twelve months, and 481.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 90.83% and 234.70%, respectively. Furthermore, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have a Relative Strength Index (RSI) of 77.89. The free research report on MRNS is available at:

http://dailystocktracker.com/registration/?symbol=MRNS NewLink Genetics 

Ames, Iowa headquartered NewLink Genetics Corp.'s stock finished last Friday's session 3.88% higher at $10.18. A total volume of 3.48 million shares was traded, which was above their three months average volume of 2.20 million shares. The Company's shares have gained 43.38% in the last month and 38.50% over the previous three months. The stock is trading above its 50-day average by 16.58%. Furthermore, shares of NewLink Genetics, which focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer, have an RSI of 49.70.

On September 11th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $14 a share to $29 a share. The complimentary report on NLNK can be downloaded at:

http://dailystocktracker.com/registration/?symbol=NLNK Akcea Therapeutics 

At the close of trading on Friday, shares in Cambridge, Massachusetts headquartered Akcea Therapeutics Inc. saw a drop of 2.33%, ending the day at $27.67. The stock recorded a trading volume of 602,052 shares, which was higher than its three months average volume of 587.40 thousand shares. The Company's shares have advanced 33.35% in the last month and 191.88% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 45.74% and 50.86%, respectively. Moreover, shares of Akcea Therapeutics, which focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the US and internationally, have an RSI of 67.44. Visit us today and download our complete research report on AKCA for free at:

http://dailystocktracker.com/registration/?symbol=AKCA Amgen 

Thousand Oaks, California headquartered Amgen Inc.'s shares ended the day 0.53% higher at $186.45 with a total trading volume of 3.01 million shares, which was above their three months average of 2.49 million shares. The stock has gained 12.69% over the last twelve months and 27.52% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 4.97% and 11.49%, respectively. Additionally, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have an RSI of 60.34.

On September 28th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $183 a share to $198 a share. Get free access to your technical report on AMGN at:



Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Email: [email protected] 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com

© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN
03/15AMGEN : Researchers from Amgen Report New Studies and Findings in the Area of Bi..
03/15AMGEN : New Analyses Show Payer Utilization Management Criteria Deny Access to P..
03/12Praluent lowers risk of death; Sanofi, Regeneron offer lower price
03/08AMGEN : To Present New Data From Repatha® evolocumab Clinical Trials At ACC.18
03/07AMGEN : Announces 2018 Second Quarter Dividend
03/07AMGEN : To Present At the Cowen and Company 38th Annual Health Care Conference
03/07AMGEN : Economic burden of CVD in Saudi Arabia to jump to $9.8bn by 2035
03/06CYTOKINETICS : to Present at March Investor Conferences
03/05AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
03/01AMGEN : New Autoimmune Diseases and Conditions Findings Has Been Reported by Inv..
More news
News from SeekingAlpha
03/18TOPS OF 44 'SAFER' DIVIDEND NASDAQ E : Comcast By Gain; Vodafone By Yield For Ma.. 
03/17Top 52 Nasdaq Stocks By Yield, Upside & Gains For March 
03/13Amgen (AMGN) Presents At 38th Annual Cowen And Company Healthcare Conference .. 
03/12The MnM Portfolio, February 2018 - Employer Contributions Boost The Portfolio.. 
03/12ODYSSEY OUTCOMES : Making Regeneron's Stock Great Again?